Novo Holdings Portfolio Company Amolyt Pharma Enters into Definitive Agreement to be Acquired by AstraZeneca

Optimum Strategic Communications United Kingdom Denmark United States of America

Deal value up to US$1.05 billionNovo Holdings co-led Series A financing in Amolyt, supported additional financings and is Amolyt's largest investor Acquisition validates Novo Holdings' strategy to identify and invest long term in high quality European biotech companiesView original content:https://www.prnewswire.co.uk/news-releases/novo-holdings-portfolio-company-amolyt-pharma-enters-into-definitive-agreement-to-be-acquired-by-astrazeneca-302089163.html